Bristol-Myers Squibb 3Q 3Q Revenues: $5.5 billion (+4%) 3Q Earnings: $1.3 billion (-54%) YTD Revenues: $15.9 billion (+4%) YTD Earnings: $3.5 billion (-26%) Comments: Biopharmaceutical sales were $4.8 billion (+6%). Plavix sales were $1.6 billion (+8%). Sales of Abilify were $653 million (+16%). Reyataz sales were $360 million (+5%). Sustiva Franchise revenue was $315 million (+7%). Erbitux sales were down 3% to $179 million. Sprycel sales were up 30% to $107 million. R&D...